Skip to main content
Fig. 4 | Trials

Fig. 4

From: Hyperhydration to Improve Kidney Outcomes in Children with Shiga Toxin-Producing E. coli Infection: a multinational embedded cluster crossover randomized trial (the HIKO STEC trial)

Fig. 4

The conservative fluid management pathway leaves the decision to admit the child to the discretion of the clinical care team. If microangiopathy is present admission is encouraged. For inpatients and outpatients, laboratory monitoring should be performed a minimum of every 24 h until discharge criteria are met. If intravenous fluids are administered, the maximum rate is 100% of maintenance and the target is euvolemia and maintaining weight gain below < 5%. The pathway should be discontinued once the same criteria are achieved as for the hyperhydration pathway (Fig. 3)

Back to article page